Jane Guan

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

Carol O’Brien, Jeffrey J. Wallin, Deepak Sampath et al. · Clinical Cancer Research · 2010 · 257 citations · Full text

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan et al. · Molecular Cancer Therapeutics · 2011 · 226 citations

Chemoprevention Strategy, Cancer Biology, Pd Biomarkers +20

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Jane Guan, Wei Zhou, Marc Hafner et al. · Cell · 2019 · 215 citations · Full text

Signal Transduction, Endocrine Mechanism, Medicine +8

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer

Jun Liang, Robert A. Blake, Jae H. Chang et al. · Journal of Medicinal Chemistry · 2021 · 130 citations · Full text

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death <i>In Vitro</i> and <i>In Vivo</i>

Jeffrey J. Wallin, Jane Guan, Wei Wei Prior et al. · Clinical Cancer Research · 2012 · 85 citations